Details of the Drug

General Information of Drug (ID: DMRICNP)

Drug Name
Vandetanib
Synonyms
Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 475.4
Topological Polar Surface Area (xlogp) 4.9
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 19 days [4]
Metabolism
The drug is metabolized via plasma [5]
Vd
The volume of distribution (Vd) of drug is 7450 L [6]
Chemical Identifiers
Formula
C22H24BrFN4O2
IUPAC Name
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
Canonical SMILES
CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC
InChI
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
InChIKey
UHTHHESEBZOYNR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3081361
ChEBI ID
CHEBI:49960
CAS Number
443913-73-3
DrugBank ID
DB05294
TTD ID
D0G6QF
VARIDT ID
DR00618
INTEDE ID
DR1669
ACDINA ID
D00720

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [7], [8]
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Inhibitor [7], [8]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [7], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor receptor 2 (KDR) DTT KDR 1.98E-01 0.11 0.2
Breast cancer resistance protein (ABCG2) DTP BCRP 9.45E-01 -5.34E-02 -9.01E-02
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 9.69E-01 1.16E-03 3.56E-03
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 8.15E-01 6.20E-03 5.61E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vandetanib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [69]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Vandetanib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [70]
Coadministration of a Drug Treating the Disease Different from Vandetanib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Vandetanib and Ivosidenib. Acute myeloid leukaemia [2A60] [70]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Vandetanib and Midostaurin. Acute myeloid leukaemia [2A60] [70]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Vandetanib and Arn-509. Acute myeloid leukaemia [2A60] [70]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Vandetanib and Oliceridine. Acute pain [MG31] [70]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Ivabradine. Angina pectoris [BA40] [71]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Vandetanib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [70]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Vandetanib and Levalbuterol. Asthma [CA23] [72]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Vandetanib caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [73]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Vandetanib and Eribulin. Breast cancer [2C60-2C6Y] [70]
Talazoparib DM1KS78 Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [74]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Vandetanib and Bosutinib. Breast cancer [2C60-2C6Y] [70]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Vandetanib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [75]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Vandetanib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [72]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Vandetanib and Osilodrostat. Cushing syndrome [5A70] [70]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Vandetanib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [76]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Vandetanib and Deutetrabenazine. Dystonic disorder [8A02] [70]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Vandetanib and Ingrezza. Dystonic disorder [8A02] [70]
Cenobamate DMGOVHA Moderate Increased metabolism of Vandetanib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [77]
Dexlansoprazole DM1DBV5 Minor Decreased absorption of Vandetanib due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [69]
Ripretinib DM958QB Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [69]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [78]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Vandetanib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [70]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Vandetanib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [70]
Aliskiren DM1BV7W Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [70]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Polyethylene glycol. Irritable bowel syndrome [DD91] [79]
Naloxegol DML0B41 Minor Decreased clearance of Vandetanib due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [80]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Vandetanib and Crizotinib. Lung cancer [2C25] [70]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Vandetanib and Osimertinib. Lung cancer [2C25] [70]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Vandetanib and Selpercatinib. Lung cancer [2C25] [70]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Vandetanib and Lumefantrine. Malaria [1F40-1F45] [69]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Vandetanib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [70]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Vandetanib and Idelalisib. Mature B-cell leukaemia [2A82] [81]
GDC-0199 DMH0QKA Major Decreased clearance of Vandetanib due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [69]
IPI-145 DMWA24P Moderate Increased metabolism of Vandetanib caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [82]
Arry-162 DM1P6FR Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Arry-162. Melanoma [2C30] [69]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Vandetanib and LGX818. Melanoma [2C30] [70]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Vandetanib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [71]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Vandetanib and Panobinostat. Multiple myeloma [2A83] [70]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Siponimod. Multiple sclerosis [8A40] [69]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Fingolimod. Multiple sclerosis [8A40] [70]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Vandetanib and Ozanimod. Multiple sclerosis [8A40] [70]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Vandetanib and Romidepsin. Mycosis fungoides [2B01] [70]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Vandetanib and Rucaparib. Ovarian cancer [2C73] [70]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Vandetanib and Triclabendazole. Parasitic worm infestation [1F90] [70]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Vandetanib and Pimavanserin. Parkinsonism [8A00] [70]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Vandetanib and Macimorelin. Pituitary gland disorder [5A60-5A61] [83]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Vandetanib and Lefamulin. Pneumonia [CA40] [70]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Vandetanib and Degarelix. Prostate cancer [2C82] [70]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Vandetanib and ABIRATERONE. Prostate cancer [2C82] [70]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Vandetanib and Enzalutamide. Prostate cancer [2C82] [70]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Vandetanib and Relugolix. Prostate cancer [2C82] [70]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Vandetanib and Amisulpride. Schizophrenia [6A20] [70]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Vandetanib and Asenapine. Schizophrenia [6A20] [70]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Vandetanib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [71]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Vandetanib and Pitolisant. Somnolence [MG42] [70]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Vandetanib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [70]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Vandetanib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [84]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [69]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Vandetanib and Lenvatinib. Thyroid cancer [2D10] [70]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Vandetanib and Cabozantinib. Thyroid cancer [2D10] [70]
⏷ Show the Full List of 60 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Brushite E00392 104805 Diluent
Crospovidone E00626 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 300 E00651 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Vandetanib 100 mg tablet 100 mg Oral Tablet Oral
Vandetanib 300 mg tablet 300 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5717).
2 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
8 Clinical pipeline report, company report or official report of AstraZeneca (2009).
9 Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46.
10 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
11 FDA label of Vandetanib. The 2020 official website of the U.S. Food and Drug Administration.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
22 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
23 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
24 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
25 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
26 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
27 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
28 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
29 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
30 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
31 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
32 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
33 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
34 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
35 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
36 FDA Drug Development and Drug Interactions
37 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
38 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
39 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
40 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
41 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
42 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
43 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
44 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
45 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
46 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
47 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
48 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
49 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
50 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
51 Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
52 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
53 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
54 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
55 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
56 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
57 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
58 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
59 National Cancer Institute Drug Dictionary (drug name Zeteletinib).
60 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
61 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
62 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
63 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
64 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
65 Clinical pipeline report, company report or official report of Exelixis (2011).
66 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
67 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
68 YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80.
69 Cerner Multum, Inc. "Australian Product Information.".
70 Canadian Pharmacists Association.
71 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
72 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
73 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
74 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
75 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
76 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
77 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
78 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
79 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
80 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
81 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
82 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
83 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
84 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.